Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLD2 | O14939 | 4/20 | 0.53 |
| ▸ | PLD1 | Q13393 | 3/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.50 |
| ▸ | HTR7 | P34969 | 3/20 | 0.50 |
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
| ▸ | DRD3 | P35462 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 2/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.50 |
| ▸ | DRD4 | P21917 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.50 |
| ▸ | HRH1 | P35367 | 2/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.50 |
| ▸ | HTR2B | P41595 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6246361 | 0.96 | OPRM1 (0.55) | PLD2PLD1OPRM1HTR7DRD2 | |
| SCHEMBL6249662 | 0.95 | DRD2 (0.53) | PLD2PLD1OPRM1HTR7DRD2 | |
| SCHEMBL6250724 | 0.93 | PLD2 (0.53) | PLD2PLD1OPRM1HTR7DRD2 | |
| SCHEMBL6248421 | 0.92 | PLD2 (0.55) | PLD2PLD1OPRM1HTR7DRD2 | |
| SCHEMBL6247443 | 0.92 | PLD2 (0.47) | PLD2PLD1OPRM1HTR7DRD2 | |
| SCHEMBL6249414 | 0.91 | OPRM1 (0.50) | PLD2PLD1OPRM1HTR7DRD2 | |
| SCHEMBL6248322 | 0.90 | PLD2 (0.53) | PLD2PLD1OPRM1HTR7DRD2 | |
| SCHEMBL6249241 | 0.90 | OPRM1 (0.58) | PLD2PLD1OPRM1HTR7DRD2 | |
| SCHEMBL6250247 | 0.89 | PLD2 (0.55) | PLD2PLD1OPRM1HTR7DRD2 | |
| SCHEMBL6249701 | 0.89 | OPRM1 (0.47) | PLD2PLD1OPRM1HTR7DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1256575-B1 | PHENOXYALKYLAMINE DERIVATIVES USEFUL AS OPIOID DELTA RECEPTOR AGONISTS | MEIJI SEIKA KAISHA (JP) | 2005-08-17 | — | — | EP | disclosed |
| US-6916822-B2 | Phenoxyalkylamine derivatives useful as opioid δ receptor agonists | MEIJI SEIKA KAISHA, LTD. (JP) | 2005-07-12 | — | — | US | disclosed |
| US-20050148583-A1 | Phenoxyalkylamine derivatives useful as opioid delta receptor ligands | MEIJI SEIKA KAISHA, LTD. (JP) | 2005-07-07 | — | — | US | disclosed |
| US-20030171370-A1 | Phenoxyalkylamine derivatives useful as opioid receptor agonists | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-09-11 | — | — | US | disclosed |
| EP-1256575-A1 | PHENOXYALKYLAMINE DERIVATIVES USEFUL AS OPIOID DELTA RECEPTOR AGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171370-A1 | Phenoxyalkylamine derivatives useful as opioid receptor agonists | OPRM1, OPRK1, OPRD1 | PLD2 956/4885PLD1 1680/4885OPRM1 1/4885 |
| US-20050148583-A1 | Phenoxyalkylamine derivatives useful as opioid delta receptor ligands | OPRD1, OPRM1, OPRK1 | PLD2 945/4885PLD1 1227/4885OPRM1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.